Le Lézard
Classified in: Health, Covid-19 virus
Subject: CCA

Valeo Pharma To Report Third Quarter 2021 Results and Hold Investors Conference Call / Webcast


MONTREAL, Sept. 16, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2021 on Wednesday September 22, 2021 after market close.

Valeo will host a conference call to discuss those results and highlights on Thursday September 23, 2021 at 8.30am (ET). The telephone numbers to access the conference call are 1-888-664-6392 and 416-764-8659. An audio replay of the call will be available. The numbers to access the audio replay are 1-888-390-0541 and 416-764-8677 using the following access code (326073#).

A live audio webcast of the conference call will be available via: https://produceredition.webcasts.com/starthere.jsp?ei=1493192&tp_key=bd0508d9b1

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.

Forward Looking Statements

This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE Valeo Pharma Inc.


These press releases may also interest you

at 09:35
Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection
Two large multi-state studies uncovered a highly effective way to improve antibiotic selection for patients hospitalized with pneumonia or urinary tract infections (UTI), enabling better antibiotic stewardship in hospitals, according to research...

at 09:25
United States Telehealth Weight Loss Market Report 2024-2028: Impacts of COVID and GLP-1 Meds Featuring Weight Watchers, Noom, Ro.co, , AmWell, Amazon, Teladoc, Form Health, Form Health Among Others - ResearchAndMarkets.com
The "The U.S. Telehealth Weight Loss Market" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering The report includes in-depth analyses of: the scope of telehealth usage in the U.S., telehealth user demographics, pros and...

at 09:00
Inaugural 'Korea Medical Innovation Research Forum' regular seminar, a success
Amid growing concerns about a medical crisis as a result of acute conflict between the government...

at 08:45
Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against QuidelOrtho Corporation
Wolf Haldenstein Adler Freeman & Herz LLP  ("Wolf  Haldenstein") announces that a federal securities class action lawsuit has been filed in the United States District Court for the Southern  District of New York on behalf of investors who purchased...

at 08:00
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
Sunshine Biopharma Inc. , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, is happy to announce that its wholly owned generic pharmaceutical subsidiary, Nora...

at 07:00
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") for violations of 10(b) and 20(a) of the Securities...

More news about Covid-19 virus...


News published on and distributed by: